Physician profile
Andrew S Berg
NPI 1548383789
$244,765.50
in general payments reported to CMS, 2019-2025
37 companies · $89K in 2025
The $89K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $21K · 2022: $41K · 2023: $30K · 2024: $64K · 2025: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $139K · Food and Beverage: $21K · Travel and Lodging: $13K · Consulting Fee: $10K · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $139,195.00 |
| Food and Beverage | $21,022.94 |
| Travel and Lodging | $13,022.22 |
| Consulting Fee | $10,361.00 |
| Education | $111.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $63,825.23 | 2021-2025 | Tremfya |
| Ucb, INC. | $60,352.00 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $35,332.49 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $28,465.41 | 2021-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $23,995.81 | 2021-2025 | Tremfya |
| Galderma Laboratories, L.P. | $5,068.64 | 2021-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $4,293.96 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $3,432.61 | 2021-2025 | Adbry, Anzupgo |
| Abbvie INC. | $3,382.17 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $2,713.55 | 2021-2025 | |
| Lilly USA, LLC | $2,010.57 | 2021-2025 | Olumiant, Taltz, Ebglyss |
| Arcutis Biotherapeutics, INC. | $1,977.17 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $1,923.42 | 2021-2025 | Winlevi, Ilumya, Blu-U |
| Journey Medical Corporation | $1,301.83 | 2021-2025 | |
| Stemline Therapeutics INC. | $1,288.63 | 2021-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Berg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.